Use of tlr agonist in combination with immune checkpoint inhibitor and vegfr inhibitor in the preparation of drugs for treating tumors

An immune checkpoint and inhibitor technology, which can be used in anti-tumor drugs, anti-animal/human immunoglobulins, drug combinations, etc., and can solve problems such as no results.

Active Publication Date: 2022-05-24
JIANGSU HENGRUI MEDICINE CO LTD +2
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] MEDIMMUNE has launched a clinical trial on the combination of TLR / 8 agonist MEDI9197 and durvalumab in the treatment of solid tumors or T-cell lymphoma, but there is no result yet (NCT02556463)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of tlr agonist in combination with immune checkpoint inhibitor and vegfr inhibitor in the preparation of drugs for treating tumors
  • Use of tlr agonist in combination with immune checkpoint inhibitor and vegfr inhibitor in the preparation of drugs for treating tumors
  • Use of tlr agonist in combination with immune checkpoint inhibitor and vegfr inhibitor in the preparation of drugs for treating tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0134] Example 1. Preclinical research Compound dihydrochloride of formula (I) (Drug A), PD-1 antibody (Drug B), and apatinib mesylate in huPD of murine colon cancer MC38 -1 Pharmacodynamic evaluation on humanized transgenic mouse animal model

[0135] 1. Experimental materials

[0136] Tumor cells: MC38 tumor cells, P7 generation was purchased from Nanjing Galaxy Bio-Pharmaceutical Co., Ltd. The cells were cultured in RPMI1640 medium containing 10% fetal bovine serum. The cells were adherent cells and were routinely digested and passaged with EDTA-containing trypsin. They were passaged twice a week and placed in a 37°C, 5% CO2 incubator for continued culture. . Tumor cells in logarithmic growth phase were used for the establishment of in vivo xenograft models.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This application relates to the use of TLR agonists in combination with immune checkpoint inhibitors and VEGFR inhibitors in the preparation of drugs for treating tumors. Specifically, the TLR agonist involved in this application is a compound represented by formula (I) or its complex or a pharmaceutically acceptable salt thereof, and the immune checkpoint inhibitor is selected from PD‑1 inhibitors, PD‑L1 inhibitors or CTLA ‑4 inhibitor, the VEGFR inhibitor is apatinib or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The present application relates to the use of a TLR agonist in combination with an immune checkpoint inhibitor and a VEGFR inhibitor in the preparation of a medicament for treating tumors. Background technique [0002] Protein programmed death 1 (PD-1) is an inhibitory member of the CD28 receptor family, which also includes CD28, CTLA-4, ICOS and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells. The original members of the family, CD28 and ICOS, were discovered based on the functional effect of adding monoclonal antibodies on enhancing T cell proliferation. PD-1 was discovered by screening for differential expression in apoptotic cells. Currently, Ono's Nivolumab and Merck's Pembrolizumab have been successfully approved for marketing for the treatment of unresectable or metastatic melanoma, non-small cell lung cancer, advanced renal cell carcinoma, Hodgkin's lymphoma, recurrent or metastatic disease Squamous cell carcinoma, et...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/519A61K31/444A61K45/06A61K39/395A61P35/00C07K16/28
CPCA61K31/519A61K31/444A61K45/06A61K39/39566A61K39/39558A61P35/00C07K16/2818C07K2317/565C07K2317/24A61K2300/00
Inventor 黄晓星张岚林侃廖成张连山孙飘扬
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap